Harvard Bioscience Inc (HBIO) stock
HBIONasdaqLaboratory Analytical InstrumentsFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 10, 2026Score 3/3040% above fair value
$9.00−0.08 (-0.88%)
Close on Nov 18, 2026Market cap $40.97MP/E –Yield –
Harvard Bioscience operating cash flow
Operating cash flow is the cash the business generates from its day-to-day operations.
Harvard Bioscience's operating cash flow for the twelve months ending Jun 30, 2026 was $651.00K, down 90.2% year over year. For fiscal 2025 it was $6.73M, up 367.3% from the year before. Over ten years it grew 25.3% a year on average. The highest annual figure on record is $16.51M in fiscal 2009.
Annual operating cash flow
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $6.73M | +367.3% |
| FY2024 | Dec 31, 2024 | $1.44M | -89.7% |
| FY2023 | Dec 31, 2023 | $14.03M | +1117.7% |
| FY2022 | Dec 31, 2022 | $1.15M | -8.7% |
| FY2021 | Dec 31, 2021 | $1.26M | -86.5% |
| FY2020 | Dec 31, 2020 | $9.33M | +16.0% |
| FY2019 | Dec 31, 2019 | $8.05M | +179.0% |
| FY2018 | Dec 31, 2018 | $2.88M | +172.8% |
| FY2017 | Dec 31, 2017 | $1.06M | -80.4% |
| FY2016 | Dec 31, 2016 | $5.38M | +663.5% |
| FY2015 | Dec 31, 2015 | $705.00K | -83.8% |
| FY2014 | Dec 31, 2014 | $4.35M | +7.2% |
| FY2013 | Dec 31, 2013 | $4.06M | -49.6% |
| FY2012 | Dec 31, 2012 | $8.06M | +21.3% |
| FY2011 | Dec 31, 2011 | $6.65M | -45.9% |
| FY2010 | Dec 31, 2010 | $12.29M | -25.5% |
| FY2009 | Dec 31, 2009 | $16.51M | – |
Quarterly operating cash flow
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q2 FY2026 | Jun 30, 2026 | $325.00K | -88.2% |
| Q1 FY2026 | Mar 31, 2026 | -$662.00K | -122.2% |
| Q4 FY2025 | Dec 31, 2025 | -$96.00K | -105.6% |
| Q3 FY2025 | Sep 30, 2025 | $1.08M | – |
| Q2 FY2025 | Jun 30, 2025 | $2.76M | – |
| Q1 FY2025 | Mar 31, 2025 | $2.99M | +112.8% |
| Q4 FY2024 | Dec 31, 2024 | $1.73M | -59.9% |
| Q3 FY2024 | Sep 30, 2024 | -$842.00K | -119.3% |
| Q2 FY2024 | Jun 30, 2024 | -$846.00K | -123.8% |
| Q1 FY2024 | Mar 31, 2024 | $1.40M | -22.6% |
| Q4 FY2023 | Dec 31, 2023 | $4.30M | +60.6% |
| Q3 FY2023 | Sep 30, 2023 | $4.36M | +572.0% |
| Q2 FY2023 | Jun 30, 2023 | $3.55M | – |
| Q1 FY2023 | Mar 31, 2023 | $1.81M | – |
| Q4 FY2022 | Dec 31, 2022 | $2.68M | +2189.7% |
| Q3 FY2022 | Sep 30, 2022 | $649.00K | – |
| Q2 FY2022 | Jun 30, 2022 | -$190.00K | -124.7% |
| Q1 FY2022 | Mar 31, 2022 | -$1.99M | -291.5% |
| Q4 FY2021 | Dec 31, 2021 | $117.00K | -95.3% |
| Q3 FY2021 | Sep 30, 2021 | -$660.00K | -141.3% |
| Q2 FY2021 | Jun 30, 2021 | $768.00K | -67.6% |
| Q1 FY2021 | Mar 31, 2021 | $1.04M | -63.9% |
| Q4 FY2020 | Dec 31, 2020 | $2.49M | +12.2% |
| Q3 FY2020 | Sep 30, 2020 | $1.60M | -49.4% |
| Q2 FY2020 | Jun 30, 2020 | $2.37M | +261.2% |
| Q1 FY2020 | Mar 31, 2020 | $2.87M | +42.8% |
| Q4 FY2019 | Dec 31, 2019 | $2.22M | -14.4% |
| Q3 FY2019 | Sep 30, 2019 | $3.16M | – |
| Q2 FY2019 | Jun 30, 2019 | $657.00K | -48.6% |
| Q1 FY2019 | Mar 31, 2019 | $2.01M | +348.7% |
| Q4 FY2018 | Dec 31, 2018 | $2.59M | – |
| Q3 FY2018 | Sep 30, 2018 | -$1.43M | -167.3% |
| Q2 FY2018 | Jun 30, 2018 | $1.28M | +168.8% |
| Q1 FY2018 | Mar 31, 2018 | $448.00K | – |
| Q4 FY2017 | Dec 31, 2017 | -$939.00K | -154.4% |
| Q3 FY2017 | Sep 30, 2017 | $2.13M | -38.1% |
| Q2 FY2017 | Jun 30, 2017 | $475.00K | – |
| Q1 FY2017 | Mar 31, 2017 | -$610.00K | – |
| Q4 FY2016 | Dec 31, 2016 | $1.73M | – |
| Q3 FY2016 | Sep 30, 2016 | $3.44M | – |
See a number that looks wrong?